Federal regulators are again delaying a decision on whether to approve the highly touted experimental anticlotting drug Eliquis developed by Pfizer and Bristol-Myers Squibb.
The drugmakers say the Food and Drug Administration is asking for more information from a huge international study that examined stroke prevention in patients with an irregular heartbeat called atrial fibrillation. The companies say regulators are not asking for any new studies.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.